AMGEN INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 305.8 USD | +1.59% |
|
-0.01% | +6.17% |
| 05-28 | US FDA approves Amgen's biosimilar to AstraZeneca's rare blood disorder treatment | RE |
| 05-28 | Amgen's Rare-Disease Treatment Biosimilar Bkemv Gets FDA Approval | DJ |
ETFs positioned on Amgen Inc.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 7.84% | 0 M€ | 0.00% | - | |
| 7.63% | 0 M€ | 0.00% | - | |
| 5.08% | 116 M€ | +12.74% | - | |
| 3.71% | 17 M€ | +6.09% | - | |
| 3.24% | 1 M€ | -.--% | - | |
| 2.61% | 1 M€ | +2.21% | - | |
| 1.75% | 4,592 M€ | -.--% | ||
| 1.73% | 9 M€ | -4.31% | - | |
| 1.67% | 9 M€ | -.--% | - | |
| 1.65% | 8 M€ | -.--% | ||
| 1.55% | 800 M€ | +5.69% | ||
| 1.37% | 2 M€ | +20.44% | - | |
| 1.31% | 5 M€ | -72.95% | - | |
| 1.29% | 3 M€ | -.--% | - | |
| 1.19% | 15 M€ | -.--% | - | |
| 1.04% | 3,859 M€ | +18.82% | - | |
| 1.04% | 469 M€ | -2.05% | ||
| 1.04% | 1,100 M€ | +2.49% | ||
| 0.88% | 2 M€ | -.--% | ||
| 0.77% | 265 M€ | +4.04% | - | |
| 0.75% | 7 M€ | +0.11% | - |
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows:
- drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.;
- other (5.8%): primarily royalties.
The United States account for 70.3% of net sales.
Sector
Pharmaceuticals
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
305.8
USD
Average target price
316.3
USD
Spread / Average Target
+3.41%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +6.17% | 164B | |
| +40.73% | 739B | |
| +32.83% | 598B | |
| -6.30% | 353B | |
| +15.15% | 318B | |
| +4.05% | 285B | |
| +15.00% | 240B | |
| +9.78% | 210B | |
| -5.52% | 206B | |
| -0.45% | 162B |
- Stock Market
- Equities
- AMGN Stock
- Funds and ETFs Amgen Inc.
